Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

CONCLUSION: Treated progression of DLBCL increases adjusted PPPM costs by over $8000 compared with no progression.PMID:37704514 | DOI:10.1016/j.clml.2023.08.005
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research